{"id":451244,"date":"2021-03-04T16:08:23","date_gmt":"2021-03-04T21:08:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451244"},"modified":"2021-03-04T16:08:23","modified_gmt":"2021-03-04T21:08:23","slug":"ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/","title":{"rendered":"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">COPENHAGEN, Denmark, March  04, 2021  (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on\u00a0Wednesday, March 10, 2021\u00a0at\u00a04:30 p.m. Eastern Time\u00a0(ET) to review its 2020 financial results and provide a business update.<\/p>\n<p>\n        <strong>Conference Call Details<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <strong>Date<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">Wednesday, March 10, 2021<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <strong>Time<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">4:30 p.m. ET\/1:30 p.m. Pacific Time<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <strong>Dial In (U.S.)<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">844-290-3904<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <strong>Dial In (International)<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">574-990-1036<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <strong>Access Code<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">1996657<\/td>\n<\/tr>\n<\/table>\n<p>A live webcast of the conference call will be available on the Investors and News section of the\u00a0Ascendis Pharma\u00a0website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5liXY_4a05CEVg-5EWqUT4ZjBvgsCiqnYP46-8vZZpt8dkfSy7xwY3mCBH_I9YRIh28XlgFupnHfX-xVeQ6EF3_Q5dBLgxfED4l6WMjHtgU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.ascendispharma.com<\/u><\/a>. A webcast replay will be available on this website shortly after conclusion of the event for 30 days.<\/p>\n<p>\n        <strong>About\u00a0Ascendis Pharma A\/S\u00a0<\/strong>\n      <\/p>\n<p>Ascendis Pharma\u00a0is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients\u2019 lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.<\/p>\n<p>Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to expand into additional therapeutic areas to address unmet patient needs.<\/p>\n<p>Ascendis is headquartered in\u00a0Copenhagen, Denmark, with additional offices in Heidelberg and\u00a0Berlin, Germany,\u00a0Palo Alto\u00a0and\u00a0Redwood City, California, and\u00a0Princeton, New Jersey.<\/p>\n<p>Please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5liXY_4a05CEVg-5EWqUT4ZjBvgsCiqnYP46-8vZZpvJBLW1k1bmdZgPeWp7r7oI_NJa6V537cC8fB64j9yPcd56vm2Ifuzijs5zS6_RHyY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ascendispharma.com<\/a> (for global information) or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5liXY_4a05CEVg-5EWqUT411BjJrjNWTwNXQi6hk2awOCkT1LIOfHv4zgGm33_PKINcMS4oMF8ThYUZR97Tx2gCdNbc2_RBHZuvYyTkCdnA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ascendispharma.us<\/a> (for U.S. information.)<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis\u2019 future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis\u2019 ability to apply its TransCon technologies to build a leading, fully integrated biopharmaceutical company, (ii) Ascendis\u2019 product pipeline and expansion into additional therapeutic areas and (iii) Ascendis\u2019 expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis\u2019 business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis\u2019 ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis\u2019 business in general, see Ascendis\u2019 prospectus supplement filed on\u00a0July 9, 2020\u00a0and Ascendis\u2019 current and future reports filed with, or submitted to, the\u00a0U.S. Securities and Exchange Commission\u00a0(SEC), including its Annual Report on Form 20-F filed with the\u00a0SEC\u00a0on\u00a0April 3, 2020. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.<\/p>\n<p>\n        <em>Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. \u00a9 March 2021 Ascendis Pharma A\/S.<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:50%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:52%;width:52%;min-width:52%\">\n            <strong><br \/>\n              <u>Investor contacts:<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"max-width:48%;width:48%;min-width:48%\">\n            <strong><br \/>\n              <u>Media contact:<\/u><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Tim Lee<\/td>\n<td>Ron Rogers<\/td>\n<\/tr>\n<tr>\n<td>Ascendis Pharma<\/td>\n<td>Ascendis Pharma<\/td>\n<\/tr>\n<tr>\n<td>(650) 374-6343<\/td>\n<td>(650) 507-5208<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:tle@ascendispharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">tle@ascendispharma.com<\/a>\n          <\/td>\n<td>\n            <a href=\"mailto:rrs@ascendispharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rrs@ascendispharma.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Patti Bank<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Westwicke Partners<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>(415) 513-1284<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:patti.bank@westwicke.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">patti.bank@westwicke.com<\/a>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:ir@ascendispharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@ascendispharma.com<\/a>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e2764f50-9cca-4329-8d8b-118414075087\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on\u00a0Wednesday, March 10, 2021\u00a0at\u00a04:30 p.m. Eastern Time\u00a0(ET) to review its 2020 financial results and provide a business update. Conference Call Details Date Wednesday, March 10, 2021 Time 4:30 p.m. ET\/1:30 p.m. Pacific Time Dial In (U.S.) 844-290-3904 Dial In (International) 574-990-1036 Access Code 1996657 A live webcast of the conference call will be available on the Investors and News section of the\u00a0Ascendis Pharma\u00a0website at\u00a0www.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451244","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on\u00a0Wednesday, March 10, 2021\u00a0at\u00a04:30 p.m. Eastern Time\u00a0(ET) to review its 2020 financial results and provide a business update. Conference Call Details Date Wednesday, March 10, 2021 Time 4:30 p.m. ET\/1:30 p.m. Pacific Time Dial In (U.S.) 844-290-3904 Dial In (International) 574-990-1036 Access Code 1996657 A live webcast of the conference call will be available on the Investors and News section of the\u00a0Ascendis Pharma\u00a0website at\u00a0www.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion &hellip; Continue reading &quot;Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T21:08:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascendis Pharma A\\\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10\",\"datePublished\":\"2021-03-04T21:08:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/\",\"name\":\"Ascendis Pharma A\\\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=\",\"datePublished\":\"2021-03-04T21:08:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascendis Pharma A\\\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/","og_locale":"en_US","og_type":"article","og_title":"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10 - Market Newsdesk","og_description":"COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon\u2122 technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on\u00a0Wednesday, March 10, 2021\u00a0at\u00a04:30 p.m. Eastern Time\u00a0(ET) to review its 2020 financial results and provide a business update. Conference Call Details Date Wednesday, March 10, 2021 Time 4:30 p.m. ET\/1:30 p.m. Pacific Time Dial In (U.S.) 844-290-3904 Dial In (International) 574-990-1036 Access Code 1996657 A live webcast of the conference call will be available on the Investors and News section of the\u00a0Ascendis Pharma\u00a0website at\u00a0www.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion &hellip; Continue reading \"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T21:08:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10","datePublished":"2021-03-04T21:08:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/"},"wordCount":746,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/","name":"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=","datePublished":"2021-03-04T21:08:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDgzNSM0MDQ5NTI4IzIwMTEyMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update-conference-call-on-march-10\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascendis Pharma A\/S Announces Full Year 2020 Financial Results and Business Update\u00a0Conference Call on March 10"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451244"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451244\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}